Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma.

Mazzaferro V, El-Rayes BF, Droz Dit Busset M, Cotsoglou C, Harris WP, Damjanov N, Masi G, Rimassa L, Personeni N, Braiteh F, Zagonel V, Papadopoulos KP, Hall T, Wang Y, Schwartz B, Kazakin J, Bhoori S, de Braud F, Shaib WL. · 2019

Read Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. by Mazzaferro V, El-Rayes BF, Droz Dit Busset M, Cotsoglou C, Harris WP, Damjanov N, Masi G, Rimassa L, Personeni N, Braiteh F, Zagonel V, Papadopoulos KP, Hall T, Wang Y, Schwartz B, Kazakin J, Bhoori S, de Braud F, Shaib WL. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6342954.txt.

Introduction

Mazzaferro and co-authors test derazantinib in a rare bile duct cancer. Their trial report appeared in the British Journal of Cancer. The cancer grows inside the liver and resists standard care. Some tumors carry a fused gene called FGFR2. Derazantinib is a pill that blocks that gene family. The open-label study enrolled 29 patients.

All patients had inoperable tumors with the FGFR2 fusion. Most had already failed earlier chemotherapy. Tumors shrank in about a fifth of patients. Disease was controlled in over four fifths. Median time without growth was 5.7 months. Side effects hit nearly all patients, fatigue most often. Eye problems and high phosphate were also common. The authors see promise for this targeted option.

Catalog record

CREATORMazzaferro V, El-Rayes BF, Droz Dit Busset M, Cotsoglou C, Harris WP, Damjanov N, Masi G, Rimassa L, Personeni N, Braiteh F, Zagonel V, Papadopoulos KP, Hall T, Wang Y, Schwartz B, Kazakin J, Bhoori S, de Braud F, Shaib WL.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE35 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6342954

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma By Vincenzo Mazzaferro, Bassel F El-Rayes, Michele Droz dit Busset, Christian Cotsoglou, William P Harris, Nevena Damjanov, Gianluca Masi, Lorenza Rimassa, Nicola Personeni, Fadi Braiteh, Vittorina Zagonel, Kyriakos P Papadopoulos Published in: British Journal of Cancer DOI: 10.1038/s41416-018-0334-0 ABSTRACT Abstract Background Next-generation sequencing has identified actionable genetic aberrations in intrahepatic cholangiocarcinomas (iCCA), including the fibroblast growth factor receptor 2 (FGFR2) fusions. Derazantinib (ARQ 087), an orally bioavailable, multi-kinase inhibitor with potent pan-FGFR activity, has shown preliminary therapeutic activity against FGFR2 fusion-positive iCCA. Methods This multicentre, phase 1/2, open-label study enrolled adult patients with unresectable iCCA with FGFR2 fusion, who progressed, were intolerant or not eligible to first-line chemotherapy (NCT01752920). Subjects received derazantinib in continuous daily doses. Tumour response was assessed according to RECIST 1.1 every 8 weeks. Results Twenty-nine patients (18 women/11 men; median age, 58.7 years), 2 treatment-naive and 27 who progressed after at least one prior systemic therapy, were enrolled. Overall response rate was 20.7%, disease control rate was 82.8%. Estimated median progression-free survival was 5.7 months (95% CI: 4.04–9.2 months). Treatment-related adverse events (AE) were observed in 27 patients (93.1%, all grades), including asthenia/fatigue (69.0%), eye toxicity (41.4%), and hyperphosphatemia (75.9%). Grade ≥ 3 AEs occurred in 8 patients (27.6%). Conclusion Derazantinib demonstrated encouraging anti-tumour activity and a manageable safety profile in patients with advanced, unresectable iCCA with FGFR2 fusion who progressed after chemotherapy. A pivotal trial of derazantinib in iCCA is ongoing (NCT03230318). Subject terms: Bile duct cancer, Targeted therapies INTRODUCTION Cholangiocarcinomas represent a heterogeneous group of epithelial malignancies originating from the biliary system. They are classified either as intrahepatic (arising proximally to the second order bile ducts), peri-hilar (arising from the tract between the first order bile ducts and the main bile duct, proximally to the cystic duct), or extrahepatic (arising from the distal main bile duct). Intrahepatic cholangiocarcinomas (iCCA) arising within the liver account for ~20% of all cholangiocarcinomas.1 Compared to other cholangiocarcinomas, iCCAs are more heterogeneous, differing one from another in regards to their molecular and cell biological characteristics, as well as resistance to treatment.1–3 Most patients with iCCA present with advanced, unresectable, or metastatic disease, which limits the number of available treatment options. The current first-line standard-of-care chemotherapy for patients with advanced biliary tract cancers, including iCCA, is the combination of gemcitabine plus cisplatin or other platinum-derived agents,4 with a median survival of less than 1 year.5–9 There is no proven effective treatment for patients with advanced biliary cancer who progress on first-line chemotherapy, thus identifying second-line treatment for these patients as a high unmet medical need.10,11 High degree of drug resistance is common, most likely reflecting the genetic complexity and cellular heterogeneity of iCCA.1 Prominent desmoplastic stroma seen in most tumours is yet another barrier to drug delivery. Next-generation sequencing of iCCA has identified several potentially actionable therapeutic targets. The most common aberrations are isocitrate dehydrogenase (IDH1/2) mutations12,13 and FGFR2 mutations or fusions.14–18 FGFR genetic aberrations occur in 10 to 16% of iCCAs, more frequently in younger patients (≤40 years), with a non-significant predilection for female sex.19 FGFR2 translocations are usually mutually exclusive of KRAS, IDH1/2, and BRAF mutations. Fusion events are usually present in a very high proportion of tumour cells, and most likely represent a clonal hallmark deriving from an early oncogenic “driver” mutation.15 Inhibition of FGFR2 could therefore have a high therapeutic impact. FGFR2 as an actionable target in iCCA has been tested in a number of clinical trials.20–25 FGFR2 genetic aberrations (assessed by NGS or FISH) were found to be more frequent in young and female patients with earlier tumour stage. In surgically resected patients, FGFR aberrations had a longer overall survival (OS) compared to wild-type (WT) patients, even after exclusion of patients treated with FGFR inhibitors.26,27 In fact, median OS of patients harbouring a FGFR2 aberration was longer than in WT patients (37 vs. 20 months, respectively), without any difference between FGFR2 fusions compared to other aberrations (e.g. mutations or amplifications). However, progression-free survival (PFS), available only in a subset of patients, did not show a significant difference between patients harbouring an FGFR aberration and the WT ones. One of the plausible explanations of a shorter than expected PFS may be development of recurrent secondary FGFR2 kinase domain mutations that are resistant to FGFR inhibition.25,28 Derazantinib (ARQ 087) is an orally bioavailable, potent, ATP-competitive, pan-FGFR inhibitor with strong activity against FGFR2, FGFR1, and FGFR3 kinases.29 Derazantinib demonstrated potent inhibition of tumour growth in FGFR pathway-activated models, including FGFR2-driven tumour xenografts (FGFR2 amplification/fusion, NCI-H716 and SNU-16 xenograft models), and BaF3/FGFR2 murine transfected cell lines.29 In the phase 1 part of our study, derazantinib was well tolerated with manageable toxicities in an unselected patient population, and demonstrated single-agent anti-tumour activity in heavily pretreated patients with FGFR genetic alterations.30 Recently, an open-label, dose-escalation and signal-finding phase 1/2 study (ARQ 087–101) of derazantinib in subjects with advanced solid tumours with FGFR genetic alterations, including iCCA with FGFR2 gene fusion, was completed. The study explored safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of derazantinib, and defined the recommended phase 2 dose (RP2D), based on cumulative safety data on 80 patients, showing a dose-dependent increase in toxicity when dose levels were increased from 250 to 425 mg QD.30 Herein, we report the results from the phase 1/2 of the study, which enrolled consecutive patients with FGFR2 gene fusion-positive advanced iCCA who were treated with derazantinib according to the RP2D30 (NCT01752920). METHODS Study design and treatment Patients were enrolled from August 2014 through January 2017. Two patients were treated with 400 mg daily (QD), as part of the phase 1 trial of derazantinib, while 27 patients received derazantinib at the recommended phase 2 dose (RP2D) of 300 mg QD. Treatment cycles were continuous 28-day periods without any treatment interruption between cycles. Treatment continued until disease progression, unacceptable toxicity, investigator’s decision, or consent withdrawal. Treatment with derazantinib beyond progression was permitted if, in the opinion of the Investigator, the patient continued to derive a clinical benefit. Dose interruption until resolution of toxicity, and a maximum of two dose reductions (to lower dose levels of 200 or 100 mg QD, according to the grade of toxicity), were allowed. Patients Patients with histologically confirmed unresectable or metastatic iCCA and FGFR2 gene fusion confirmed by NGS or fluorescence in situ hybridisation (FISH),31 who had progression after at least one prior systemic therapy or were treatment naive but were not eligible for standard first-line chemotherapy, were screened for enrolment. Other detailed eligibility criteria are provided in the Data Supplement. FGFR2 fusion could be determined either locally or centrally in a CLIA-certified facility. Endpoints and response assessments The primary endpoint was safety and tolerability of derazantinib in patients with advanced or unresectable FGFR2 fusion-positive iCCA. Efficacy endpoints included PFS and OS. Other secondary endpoints were overall response rate (RR; complete response [CR] + partial response [PR]) and disease control rate (DCR; CR + PR + stable disease [SD]), assessed by independent local staff radiologists, using computed tomography (CT) or magnetic resonance imaging (MRI). Radiologic response assessments were conducted at baseline and approximately every 8 weeks thereafter according to Response Evaluation Criteria in Solid Tumours (RECIST) version (v) 1.1.32

Read the complete text